The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol for a randomized controlled trial by Brian C Focht et al.
TRIALS
Focht et al. Trials 2014, 15:354
http://www.trialsjournal.com/content/15/1/354STUDY PROTOCOL Open AccessThe Individualized Diet and Exercise Adherence
Pilot Trial (IDEA-P) in prostate cancer patients
undergoing androgen deprivation therapy: study
protocol for a randomized controlled trial
Brian C Focht1,2*, Alexander R Lucas1, Elizabeth Grainger2,3, Christina Simpson2,3, Jennifer M Thomas-Ahner2,3
and Steven K Clinton2,3Abstract
Background: Androgen deprivation therapy (ADT) is the foundation of treatment for men with metastatic prostate
cancer and is now frequently incorporated into multimodality strategies for the curative treatment of locally
advanced prostate cancer. Nevertheless, the catabolic effects of ADT result in meaningful adverse effects on
physiological and quality of life outcomes, which may, in turn, increase the risk of functional decline, frailty,
cardiovascular disease, and metabolic syndrome. Recent evidence demonstrates that lifestyle intervention
promoting change in exercise and dietary behaviors is a promising approach, and may offset, or even reverse, the
adverse effects accompanying ADT. Unfortunately, the limited existing studies of the effects of exercise and dietary
interventions targeting patients with prostate cancer on ADT are characterized by high attrition rates and poor
postintervention maintenance of treatment effects. Consequently, the Individualized Diet and Exercise Adherence
Pilot Trial (IDEA-P) is designed to contrast the effects of a lifestyle intervention designed to promote independent
self-management of exercise and dietary behavior with those of standard care disease management approach in
the treatment of prostate cancer.
Methods/Design: A total of 40 patients with prostate cancer undergoing ADT will be randomly assigned to lifestyle
intervention or standard care. Outcomes of interest in IDEA-P include changes in self-reported and objectively assessed
physical function and physical activity, dietary behavior, body composition, muscular strength, and quality of life.
Outcomes will be obtained at baseline, 2-month, and 3-month assessments by trial personnel blinded to participants’
randomization assignment.
Discussion: Findings from this study will establish the feasibility and preliminary efficacy of an innovative lifestyle
intervention designed to promote progressively independent self-regulated exercise and dietary behavior change in
the treatment of patients with prostate cancer undergoing ADT.
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Despite the well-established therapeutic efficacy of andro-
gen deprivation therapy (ADT) in the treatment of prostate
cancer [1], it has become increasingly evident that men on
ADT endure lingering adverse effects as a ‘trade-off ’ for
more effective cancer control and increased longevity. The
catabolic effects of ADT result in significant adverse ef-
fects, including loss of lean muscle mass, increased fat
mass, reduced muscle strength, and lower bone mineral
density, which place men undergoing ADT at greater risk
of functional decline and frailty [2-9]. Emerging evidence
also suggests that ADT increases the risk of cardiovascular
disease and metabolic syndrome. As prolonged adminis-
tration of ADT becomes increasingly common, many men
will be required to cope with lasting treatment-related
side-effects that could meaningfully compromise their
physical function and quality of life. Prostate cancer is esti-
mated to be the cause of over half a million disability-
adjusted life years [10-12]. Thus, defining the feasibility
and efficacy of innovative interventions that preserve func-
tional abilities and quality of life and attenuate risk for
chronic disease are primary clinical considerations for pa-
tients with prostate cancer on ADT [2,7,13-17].
Exercise consistently results in improvements in relevant
physiologic and patient-reported outcomes across a variety
of cancer patients and survivors [10,18-30]. Findings from
recent randomized controlled exercise intervention trials
in patients with prostate cancer undergoing ADT also sug-
gest that exercise yields significant, clinically meaningful
improvements in muscular strength, physical function, and
quality of life [31]. Collectively, these findings provide
strong support for the beneficial role of exercise as an adju-
vant, supportive care intervention in the treatment of pa-
tients with prostate cancer. Despite the clear benefits
accompanying exercise, it is also well established within
the weight management literature that modifying both en-
ergy expenditure via increased physical activity and energy
intake through changes in dietary behavior is integral to
successful behavioral weight management interventions
[32-34]. Primary adverse effects of ADT are increases in
body fat or bodyweight and decreases in muscle mass or
strength, which in turn, place patients with prostate cancer
at increased risk of functional decline, cardiovascular dis-
ease, and metabolic syndrome. Thus, the synergistic bene-
fits of concomitant change in both exercise and dietary
behavior could represent an optimal lifestyle intervention
approach for offsetting the adverse effects experienced by
patients with prostate cancer during ADT.
Consistent with this position, recent findings revealed
that lifestyle interventions combining primarily super-
vised exercise and dietary advice yielded significant
improvements in aerobic fitness, muscular strength, self-
reported exercise participation [35], fatigue, quality of
life [36], and select bodyweight-related outcomes [37]relative to standard care [35,36] or metformin treatment
[37] in patients with prostate cancer undergoing pro-
longed ADT. Results of these trials are clearly important
in that they provide the first evidence of the feasibility and
preliminary efficacy of implementing lifestyle interventions
combining exercise and dietary modifications in the treat-
ment of patients with prostate care on ADT. Unfortu-
nately, despite these promising findings, 2 of the studies
were characterized by high attrition rates, of 44% [35] and
32% [36], respectively, at post-treatment follow-up. Add-
itionally, in one study, clinically meaningful improvements
in quality of life accompanying the 12-week lifestyle inter-
vention were not maintained at 6-month follow-up [36].
The deterioration of benefits accompanying lifestyle
interventions have been proposed to be directly related
to poor post-treatment adherence to exercise and dietary
behavior change [38-40]. Thus, given that adherence to
the desired behavior changes is an essential determinant
of the efficacy of lifestyle interventions, these findings
underscore the pressing need to explore novel approaches
to promoting successful adoption and maintenance of in-
dependent exercise and dietary behavior among patients
with prostate cancer. It has been proposed that high attri-
tion and poor adherence observed in lifestyle interventions
may be attributable to a failure to provide patients with
the self-regulatory skills necessary to adopt and maintain
independent lifestyle behavior change [40]. One new
approach based on social cognitive theory and the group
dynamics literature [41], a group-mediated cognitive be-
havioral (GMCB) lifestyle intervention, has recently pro-
duced superior adherence to exercise and dietary behavior
change and also yielded significant improvements in a var-
iety of clinically relevant outcomes for patients with pros-
tate cancer in randomized trials targeting chronic disease
patients [40,42-44]. The GMCB intervention couples exer-
cise and dietary behavior change with self-regulatory skills
counseling, to promote independent maintenance of life-
style behavior change and sustain intervention-induced
improvements in relevant outcomes. Although these find-
ings suggest that this approach holds promise for improv-
ing the utility of lifestyle exercise and dietary interventions
targeting patients with prostate cancer, the feasibility and
efficacy of implementing this approach in the treatment of
patients with prostate cancer undergoing ADT has not
been investigated. Therefore, the purpose of this pilot trial
is to examine the feasibility and preliminary efficacy of
implementing the GMCB exercise and dietary lifestyle




The Individualized Diet and Exercise Adherence Pilot
Trial (IDEA-P) is a two-arm, single-blind randomized
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a GMCB lifestyle intervention combining exercise and
dietary intervention approaches relative to those of a
standard care disease management approach on inpatients
with prostate cancer undergoing ADT (see Figure 1). Pri-
mary objectives of IDEA-P are to determine the feasibility
of delivering this specific lifestyle intervention approach to
patients with prostate cancer undergoing ADT and to ex-
plore the preliminary efficacy of the lifestyle intervention
for improving clinically relevant physiologic and quality of
life outcomes and the short-term adoption and mainten-
ance of independent, self-regulated exercise and dietary
behavior change for men undergoing androgen suppres-
sion therapy. A total of 40 patients with prostate cancer
on ADT will be randomly assigned to either lifestyle inter-
vention (n = 20) or standard care (n = 20) arms. Given that
this is a pilot study, it should be recognized that the target
patient accrual does not provide optimal statistical power
but is adequate to obtain effect size estimates necessary to
inform the design of a subsequent optimally powered ran-
domized controlled lifestyle intervention trial. Assess-
ments of the primary and secondary outcomes will be
obtained by study staff who are blinded to treatment arm
assignment at baseline, 2-month, and 3-month follow-up
screening visits.
Participant eligibility
The inclusion and exclusion criteria are designed to tar-
get the recruitment of sedentary patients with prostate
cancer undergoing ADT who are sufficiently healthy to
participate in a supervised center-based exercise inter-
vention involving both resistance and aerobic exercise.
To be eligible to participate in the IDEA-P trial, volun-
teers will meet the following inclusion criteria: (a) histo-
logically defined diagnosis of prostate cancer based upon
pathology reports and staging studies; (b) currently
undergoing ADT with a planned course of at least
3 months of continuous therapy; (c) sedentary activity
pattern with less than 60 min of structured exercise par-
ticipation per week during the past 6 months; (d) free ofFigure 1 Design of the IDEA-P trial.any serious medical condition that precludes safe partici-
pation in an exercise program, such as coronary artery
disease, severe hypertension, peripheral vascular disease,
stroke, congestive heart failure, chronic obstructive pul-
monary disease, insulin-dependent diabetes, psychiatric
disease, renal disease, liver disease, active cancer other
than skin cancer, and anemia; (e) consent to participate
from the treating oncologist and primary care physician;
(f ) willingness to accept randomization and undergo the
testing and intervention procedures.
Recruitment and randomization
Recruitment strategies include direct referral to study in-
vestigators from physicians at the Genitourinary Oncology
Disease Unit of the James Cancer Hospital and Ohio State
University Comprehensive Cancer Center and placement
of study-related advertisements and informational bro-
chures in cancer center oncologists’ offices and cancer
support newsletters. Volunteers interested in participating
in the study will complete a telephone screening to verify
eligibility. Participants determined to be eligible following
the completion of the phone screening interview are then
scheduled for the baseline screening visit. Eligible partici-
pants are randomly assigned with equal probability to each
of the two treatment arms, using a 1:1 ratio, following the
completion of the baseline screening visit. The computer-
generated randomization allocation sequence is sequen-
tially numbered and sealed in opaque envelopes. The
randomization allocation sequence is also concealed from
the study staff responsible for conducting the baseline
assessments.
Informed consent
Approval of trial protocol and informed consent docu-
ments has been obtained from the Ohio State University
Cancer Institutional Review Board (Project number 2012
C008) prior to the initiation of recruitment procedures.
All participants complete informed consent forms and
Health Insurance Portability and Accountability Act
authorization forms prior to participation in the trial.
Measures
Assessments of all study measures are obtained at baseline,
2-month, and 3-month follow-up screening visits using
measures with well-established validity and reliability, dem-
onstrated in prior exercise intervention studies [43,44].
Given that IDEA-P is a single-blind pilot trial, the outcome
assessments are obtained by trained study personnel who
are blinded to participants’ treatment assignment.
Outcome assessments
Functional battery
The functional battery includes measures of both self-
reported physical function and objective indices of
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tions will be measured using the abbreviated Late-Life
Function and Disability Inventory [45]. Functional per-
formance will be assessed using three valid and reliable
timed performance-related mobility tasks: a 400 meter
walk, a stair climb, and a lift-and-carry task [26,27,46,47].
The 400 meter walk test is completed in a corridor with
two cones spaced 20 meters apart. Individuals are
instructed to walk as quickly as they can and the time to
complete ten laps around the cones is recorded as the per-
formance measure. The stair climb task involves ascending
a set of eight stairs, turning around at the top, and then
descending. Participants are instructed to complete the
task as quickly as they can and performance is measured
as the total time (in seconds) necessary to complete the
task. The lift-and-carry test is a simulated common daily
activity test involving picking up a 10 lb container from a
shelf, walking 10 feet around a cone, and returning the
container to the starting position on the shelf. Participants
are instructed to complete the task as quickly as they can
and performance is measured as the total time (in sec-
onds) necessary to complete the task.
Mobility-related self-efficacy
Mobility-related self-efficacy is assessed by asking partici-
pants to rate their confidence in successfully completing
incrementally more challenging amounts of the 400 meter
walk and stair climb tasks. For walking self-efficacy, partic-
ipants are asked to rate their confidence on a 0 (no confi-
dence at all) to 10 (completely confident) scale in
completing two, four, six, eight, and ten laps around the
cones without stopping. For both stair climb and lift-and-
carry task self-efficacy, participants rate their confidence
in successfully completing two, four, six, eight, and ten
trips on the stairs without stopping. Mobility-related self-
efficacy scores are calculated for each task by summing
the total, dividing by the total number of ratings, and
multiplying by ten to yield a score ranging from 0 to 100.
This hierarchical procedure for assessing mobility-related
self-efficacy is consistent with Bandura’s recommendations
[41] and has been shown to be valid and reliable in prior
exercise intervention trials targeting older adults [48].
Muscular strength
Muscular strength will be assessed using standardized
one-repetition-maximum (1RM) testing protocols for
the chest press and leg extension exercises [49,50].
These 1RM tests are the standard by which muscular
strength is evaluated and have been found to be safe for
older adults. Participants are familiarized with the chest
press and leg extension machines and receive instruction
on proper form. Participants will begin 1RM testing for
each exercise by complete a warm-up set of four to six
repetitions. Participants will rate the difficulty of the setusing a 10-point difficulty scale ranging from 1 (not at
all difficult) to 10 (extremely difficult). The participant
perceptions of difficulty rating are used to choose the
first weight at which a 1RM test will be attempted. The
participant will be asked to lift the weight once and to
continue to perform single repetition lifts, separated by
at least a 2-minute rest interval, until a maximum weight
is reached and recorded as the 1RM.
Body composition
Body composition will be assessed using both the Bod
Pod system (Life Measurement Inc., Concord, CA) and
dual energy X-ray absorptiometry (iDXA; GE Health
Care Lunar, Madison, WI). The Bod Pod system uses
whole-body densitometry to determine body compos-
ition (body fat and lean body mass). Whole-body densi-
tometry is based on the determination of body mass and
body volume, since body density is equivalent to body
weight divided by body volume. The Bod Pod has well-
established validity and reliability as an assessment of
body composition [51]. The iDXA scans were used to
determine total body composition as well as percentage
body fat and fat-free mass for the trunk, arms, legs, an-
droid, and gynoid subregions. The iDXA method also
has well-established validity and reliability and has been
used to assess body composition in prior studies among
patients with prostate cancer undergoing ADT [31].
Physical activity and dietary behavior
Assessments of physical activity are obtained using ob-
jective and self-report measures. The LIFECORDER EX
accelerometer (Suzuken Kenz Inc. Limited, Japan) is
used to obtain an objective assessment of exercise and
physical activity participation. Participants wear the
LIFECORDER EX on their right hip attached to either a
waistband or belt during all waking hours, except when
showering, bathing, or swimming, for 7 consecutive days
following the completion of the baseline screening visit.
Participants record the times they put on and take off
the LIFECORDER EX on a self-monitoring log. The
LIFECORDER EX provides assessment of minutes of
light, moderate, and vigorous physical activity participa-
tion as well as calculating total daily steps taken. Con-
sistent with the metabolic demands for the targeted age
group [44], the accelerometer was set for intensity levels
of 3 to 6 metabolic equivalents (METs), corresponding
to moderate intensity physical activity, and >6 METs,
corresponding to vigorous intensity physical activity.
Self-reported physical activity is assessed using the
CHAMPS questionnaire [52] and the Leisure Time Exer-
cise Questionnaire (LTEQ) [53]. The CHAMPS ques-
tionnaire is a 41-item measure developed specifically for
the assessment of physical activity in adults 50 years and
older. The CHAMPS measure yields estimates of total
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week in all physical activities of moderate or higher in-
tensity. The LTEQ measures the self-reported frequency
of exercise participation performed in one’s leisure time
during a typical week. Participants are asked to report
the number of strenuous, moderate, and mild bouts of
exercise they perform during an average week. The
LTEQ has been shown to demonstrate adequate reliabil-
ity and validity in previous research [54]. Dietary behav-
ior is assessed using the Food Frequency Questionnaire,
developed by the Nutrition Assessment Shared Resource
of Fred Hutchinson Cancer Research Center, and 3-day
food records. The Food Frequency Questionnaire pro-
vides a validated assessment of long-term dietary pat-
terns. The three-day diet records provide information on
more recent diet habits and enable us to determine com-
pliance to the weekly dietary goals established at the
group nutrition counseling sessions, as well as general
dietary changes during the intervention.
Quality of life
Assessments of global and disease-specific indices of
quality of life will be obtained using several valid and re-
liable scales. The Medical Outcomes Study 36-item
short-form Health Survey [55] is a generic measure of
health-related quality of life, and consists of two norm-
based composite scales (mental health and physical
health) and eight subscales (physical functioning, mental
health, role-physical, role-emotional, bodily pain, general
health, vitality, and social functioning). The Satisfaction
with Life Scale [56] is a five-item measure of global life
satisfaction. Disease and function specific quality of life
measures will include the Functional Assessment of
Cancer Treatment-Prostate (FACT-P) survey [57], and
the Satisfaction with Function and Appearance (SFA)
scale [46]. The 12 items of the FACT-P scale designed to
assess concerns specific to patients with prostate cancer
will be assessed. The SFA scale comprises six items that
assess satisfaction with physical abilities and three items
assessing satisfaction with physical appearance. Symp-
toms of pain and fatigue will also be assessed. Pain will
be measured with the short-form McGill Pain Question-
naire, a valid, reliable 15-item adjective checklist that
captures sensory and affective dimensions of pain [58].
Fatigue will be measured with the Brief Fatigue Inven-
tory, a psychometrically sound nine-item measure that
assesses disease and treatment-related fatigue severity of
cancer patients [59].
Feasibility measures
Descriptive statistics for assessments of select indicators
of trial feasibility including recruitment rates, interven-
tion adherence, adverse events, and retention rates will
be calculated prospectively throughout the trial.Procedures
Volunteers expressing an interest in participating in
IDEA-P complete a phone screening interview to deter-
mine their eligibility for the study. Prior to participation
in the trial, participants make a baseline screening visit,
during which assessments of the all outcome measures
are obtained. At the beginning of the baseline screening
visit, inclusion criteria are verified and medical history,
informed consent, and Health Insurance Portability and
Accountability Act waiver documents are completed.
Participants then complete the functional performance
tasks and undergo body composition assessment and
1RM strength testing, followed by the questionnaire as-
sessments. After completion of the questionnaires, par-
ticipants receive oral and written instructions on how to
wear the accelerometer. Participants wear the acceler-
ometer for the next seven consecutive days and moni-
tors are returned to trial staff via the US postal service.
Upon completion of the baseline screening visit, partici-
pants are randomly assigned to one of the two treatment
arms (lifestyle intervention or standard care). Clearance
to exercise will be obtained from the primary care phys-
ician and treating oncologist prior to participation in
either the lifestyle intervention or standard care treatment
arms. Assessments of all outcomes are obtained using
exactly the same procedures at 2-month and 3-month
follow-up screening visits conducted by study staff blinded
to participants’ treatment group assignment.
Interventions
Exercise and dietary lifestyle intervention
The lifestyle intervention involves an 8-week, multi-
component approach designed to facilitate exercise and
dietary behavior change and promote adherence, inde-
pendent of study staff, to these behavioral modifications.
The exercise component involves a combination of aer-
obic and resistance exercise performed twice per week.
The aerobic exercise stimulus consists of 10 to 30 mi-
nutes of exercise performed at a rating of perceived ex-
ertion ranging from 11 (fairly light) to 14 (moderately
hard) on the participant’s choice of a treadmill, station-
ary cycle, or elliptical trainer. The resistance exercise
stimulus involves performing three sets of 8 repeat max-
imum to 12 repeat maximum at a rating of perceived ex-
ertion ranging from 12 (moderately hard) to 15 (hard) of
nine different exercises (leg extension, leg curl, chest
press, lat pull-down, overhead press, triceps extension,
bicep curl, calf raises, and abdominal crunch). Partici-
pants will take 1 to 2 minutes rest between each set and
all sets will be performed in a symptom-limited manner.
The exercise prescription is tailored to each individual’s
abilities and exercise tolerance and capacity. Conse-
quently, resistance exercise load, volume, and volume-
load and aerobic exercise duration and intensity will be
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increased across the intervention to reach optimal tar-
geted prescription ranges. All exercise sessions will last
1 hour in duration.
The GMCB activity counseling component, based on
social cognitive theory, is also integrated with exercise to
promote adoption and adherence to independent, self-
regulated exercise participation and participant reten-
tion. Counseling is delivered via six small group sessions
(20 to 30 minutes in duration) conducted once per week
immediately following a center-based exercise session
during months 1 and 2. Participants also receive four
brief (20 minutes) individualized activity counseling ses-
sions conducted via phone calls in months 1 to 3. The
specific content of this component includes the promo-
tion of group identity and social norms for activity;
self-monitoring; goal setting; barrier problem solving;
fostering social support; and reducing sedentary time.
The purpose of the activity-related behavioral counseling
component of the lifestyle intervention arm is to instruct
patients with prostate cancer undergoing ADT on the
use of self-regulatory skills necessary to adopt and main-
tain exercise, and, through the use of the group as an
agent of behavioral change, facilitate motivation to de-
velop and implement these behavioral skills in order to
successfully plan and undertake increasingly frequent in-
dependent exercise and participation in physical activity.
A basic principle underlying these contacts and their se-
quencing is one of gradually weaning participants from
dependency on staff and the group program toward in-
dependent self-regulation of exercise. This process is
one of a phased increase in the ratio of personal respon-
sibility in conjunction with a phased decrease in staff,
group, and clinic dependency. Thus, in contrast with
most approaches in traditional exercise interventions,
this approach places an emphasis on the regulation of
behavior and social problem-solving barriers to promote
independent exercise participation.
To foster the practice and mastery of the newly ac-
quired exercise and behavioral skills and prevent partici-
pants from becoming dependent on the expertise of
exercise staff to remain physically active, supervised
center-based exercise decreases from two sessions per
week in weeks 1 to 6 to one supervised session per week
in weeks 7 and 8 of the intervention. During weeks 7
and 8, participants have the goal of completing one
center-based exercise session independent of study staff
supervision during each week. During month 3, partici-
pants will have the goal of completing two center-based
exercise sessions independent of study staff supervision.
Participants will be provided free access to the center-
based exercise facility during all its standard operating
hours during weeks 7 to 12. While the facility is super-
vised by trained fitness staff members during this time,the participants will have no supervisory contact with
the study staff during these independent exercise ses-
sions. The advantages of the approach of integrating
counseling and the weaning from staff supervision are
that they help participants actively apply their develop-
ing exercise and behavioral skills to exercise independ-
ently while concomitantly providing them access to the
study’s exercise facility to facilitate completion of the in-
dependent exercise sessions during weeks 7 to 12. This
also allows us to evaluate uptake of independent exercise
adherence in months 2 and 3.
The dietary component of the lifestyle intervention in-
cludes 10 (30-minute) nutritional counseling sessions
with a registered dietitian. The first eight counseling ses-
sions will be conducted once per week immediately fol-
lowing a center-based exercise session during months 1
and 2. The two remaining sessions are conducted via bi-
weekly phone calls during month 3. The specific dietary
objectives are consistent with the therapeutic lifestyle
changes recommended in the Adult Treatment Panel III
Report of the National Cholesterol Education Program
[60] and the American Institute of Cancer Research [61].
The nutrition intervention encourages reductions in por-
tion size and caloric and fat consumption, together with
a gradual transition from an animal-based diet to a more
plant-rich diet while still incorporating animal foods, in-
cluding milk and meat, with an emphasis on monitoring
food proportion and portion size. Specific goals of the
dietary component include: (a) reduction in energy in-
take by 500 to 1000 kcal per day; (b) reduction in total
fats to 25 to 30%, saturated fats to 7%, and protein to
15% of total calories; (c) increase in fruit and vegetable
consumption to five servings per day; (d) intake of three
or more servings of whole grains per day and a gradual
increase to at least 25 g of dietary fiber per day. The nu-
trition counseling uses the GMCB and motivational
interviewing approaches that have been demonstrated to
be an effective approach to promote behavior change in
chronic disease [43] and cancer patients [58,59]. The nu-
trition counseling also builds upon many of the cognitive
behavioral self-management strategies utilized in the ex-
ercise intervention, including self-monitoring, building
self-efficacy, goal setting, and anticipating and overcom-
ing barriers to dietary behavior change.
Standard care
Men randomized to the standard care arm receive usual
treatment for prostate cancer, standard disease manage-
ment education, as well as educational literature describ-
ing the American Institute of Cancer Research dietary and
physical activity guidelines. To equate contact between
treatment arms to levels consistent with similar, con-
temporary lifestyle intervention trials [62,63], biweekly
20-minute phone calls will be made by Genitourinary
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will focus on routine aspects of self-management for pros-
tate cancer. As an incentive to promote retention across
the trial, men randomized to standard care will also re-
ceive two supervised exercise training sessions and dietary
counseling sessions following the completion of the
3-month assessment. Men will complete assessments of
all outcomes scheduled at baseline and in months 2 and 3.
Statistical analysis
The primary hypotheses of the IDEA-P trial are: (1) the
lifestyle intervention will be a safe, well-tolerated interven-
tion that yields acceptable recruitment, adherence, reten-
tion, and adverse event rates; (2) the lifestyle intervention
will result in superior improvements in physical function,
muscular strength, body composition, and quality of life
relative to standard care; and (3) the lifestyle intervention
will successfully promote adoption and short-term main-
tenance of independent, self-regulated exercise and dietary
behavior change at 3-month follow-up. Differences in the
longitudinally gathered outcome data collected at 2- and-
3 month follow-up assessments will be individually stan-
dardized by baseline values and evaluated using a weighted
repeated measures analysis of variance statistical model
adjusting for the effects of age and sex. All analyses will be
conducted according to the intention to treat principle
with last value carried forward imputation methods used
to account for missing data. As noted previously, the target
patient accrual does not provide optimal statistical power
but is adequate to obtain effect size estimates necessary to
inform the design of a subsequent optimally powered ran-
domized controlled lifestyle intervention trial.
Discussion
The IDEA-P trial is a single-blind, two-arm randomized
controlled pilot trial evaluating the feasibility and pre-
liminary efficacy of a GMCB lifestyle intervention ap-
proach combining individualized exercise, dietary
modification and behavioral self-regulatory skills coun-
seling in the treatment of patients with prostate cancer
undergoing ADT. Given the integral role of ADT in the
treatment of prostate cancer, there is a critical need to
determine the benefits of supportive care approaches in
reducing the adverse effects accompanying ADT. The
synergistic benefits of lifestyle interventions combining
exercise and dietary behavior change may be a particu-
larly beneficial adjuvant treatment approach for offset-
ting the adverse effects experienced by patients with
prostate cancer during ADT. Although recent findings
suggest that lifestyle interventions combining exercise
and dietary advice approaches yield significant improve-
ments in clinically relevant outcomes for patients with
prostate cancer undergoing ADT [35-37], some of these
studies have been characterized by high attrition rates[35,36] and poor postintervention maintenance of treat-
ment effects [36]. Consequently, these findings suggest
that novel approaches for improving successful adher-
ence to independent self-regulation exercise and dietary
behavior change are warranted.
The proposed pilot trial is innovative from both re-
search and clinical practice perspectives. From a re-
search perspective, IDEA-P is innovative in that it
expands knowledge from existing studies of the benefits
of lifestyle exercise and dietary interventions in patients
with prostate cancer on ADT [35-37]. Notably, it is the
first to determine the feasibility and efficacy of imple-
menting a group-based lifestyle intervention, which has
been effective in promoting both successful maintenance
of independent exercise and dietary behavior change and
superior changes in relevant functional and quality of life
outcomes in other chronic disease patients [40,42,43],
among men with prostate cancer undergoing ADT.
There are also other methodological aspects of IDEA-P
that make it innovative and different from extant re-
search on prostate cancer. For example, implementing
theory-based activity and dietary behavioral counseling
to promote behavior change expands on the primarily
psycho-educational advice-based approaches used in
prior studies. Furthermore, whereas prior investigations
have relied exclusively on self-reported physical activity as-
sessments, which consistently overestimate exercise and
physical activity participation, this study is the first to in-
clude a more accurate objective measure of physical activ-
ity. Collectively, these features distinguish IDEA-P from
prior or ongoing lifestyle interventions targeting men on
ADT. From a clinical perspective, we believe that deter-
mining the feasibility, safety, and preliminary efficacy of
implementing this lifestyle intervention approach in men
undergoing ADT will have meaningful future implications
for clinical practice for patients with prostate cancer. The
results of this feasibility study will inform the design of
larger randomized controlled lifestyle intervention trials.
If findings from larger scale efficacy trials demonstrate
meaningful benefits of implementing this lifestyle exercise
and dietary intervention in the treatment of patients with
prostate cancer undergoing ADT, such results could pro-
vide the evidence necessary to alter current standard care
practices toward the inclusion of exercise and dietary in-
terventions in the routine clinical treatment of patients
with prostate cancer.
Although findings from the IDEA-P trial could yield
meaningful implications for the role of lifestyle interven-
tions as an adjuvant behavioral approach for the treatment
of patients with prostate cancer, there are select study lim-
itations that should be acknowledged. Given that this is a
pilot trial intended to determine the safety, feasibility, and
preliminary efficacy of delivering the group-based behav-
ioral lifestyle intervention during ADT, the sample size
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differences in all relevant outcomes of interest. Addition-
ally, there are clearly other clinically relevant outcomes,
such as select biomarkers of prostate cancer and chronic
disease, that may be favorably influenced by the lifestyle
intervention but are not assessed in this pilot trial.
In summary, determining the feasibility and prelimin-
ary efficacy of the lifestyle intervention relative to the ef-
fects of standard care could have significant implications
for the treatment of patients with prostate cancer on
ADT. Findings from the present pilot trial will also pro-
vide effect size estimates necessary to inform the design
of a subsequent, large-scale definitive lifestyle interven-
tion efficacy trial, the results of which would fill a critical
gap in knowledge, addressing the utility of implementing
exercise and dietary modification in the treatment of pa-
tients with prostate cancer undergoing ADT.
Trial status
The IDEA-P trial is active with patient recruitment and
intervention delivery currently ongoing.
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